Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants

Author(s): Ruchika Yogesh, Noopur Srivastava and Syed Nasir Abbas Bukhari*

Volume 28, Issue 35, 2022

Published on: 26 August, 2022

Page: [2901 - 2913] Pages: 13

DOI: 10.2174/1381612828666220701160116

Price: $65

Abstract

Introduction: SARS-CoV-2 belongs to the coronavirus family, a large family of viruses infecting avian and mammalian hosts. Accumulated mutations over time in the genome of SARS-CoV-2 have given rise to different variants differing in type and sequence. Variants that did not affect transmissibility, infectivity, and severity have gone unnoticed, and mutations that made the virus unfit for survival were eventually deleted from the gene pool. An emerging variant in the host population needs to be monitored closely for its infection consequences. In addition, the variants of concern (VOC) need to be focused on developing effective disease-fighting regimes. As viral epidemics are better fought using effective vaccines, several vaccines have been developed and used since December 2020. The central point of the present study is the continuous variation in the genome of SARS-CoV-2, instigating the researchers to refine their modus operandi to fight against COVID-19.

Methods: Prominent medical and literature databases were searched using relevant keywords to gather study results, reports, and other data helpful in writing this narrative review.

Results: This article successfully collates information about the structure and life cycle of SARS-CoV-2, followed by types and nomenclature of mutations in SARS-CoV-2. Variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron) are current VOCs due to their widespread transmission capability and probable immune evasion. Furthermore, this review article presents information about the major vaccines available and those under development. Based on the original and new strains of SARS-CoV-2, 19 vaccines have been granted emergency use or conditional marketing approvals, 141 are under clinical development, and 194 are in preclinical development stages worldwide.

Conclusion: Continuous variation in the genome of SARS-CoV-2, presenting new VOCs frequently, has posed a compelling need to amend and evolve current and future vaccine development strategies to overpower the ever-evolving virus.

Keywords: SARS-CoV-2, coronavirus, COVID-19, mutation, multivariant vaccine, COVID-19 vaccine, spike protein, variant of concern.

« Previous Next »
[1]
Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019; 11(1): 59.
[http://dx.doi.org/10.3390/v11010059] [PMID: 30646565]
[2]
Chen B, Tian E-K, He B, et al. Overview of lethal human coronaviruses. Signal Transduct Target Ther 2020; 5(1): 89.
[http://dx.doi.org/10.1038/s41392-020-0190-2] [PMID: 32533062]
[3]
Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1] [PMID: 25720466]
[4]
Feschotte C, Gilbert C. Endogenous viruses: Insights into viral evolution and impact on host biology. Nat Rev Genet 2012; 13(4): 283-96.
[http://dx.doi.org/10.1038/nrg3199] [PMID: 22421730]
[5]
Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS-CoV-2 virus. Cell 2020; 183(3): 730-738.e13.
[http://dx.doi.org/10.1016/j.cell.2020.09.018] [PMID: 32979942]
[6]
Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3(1): 237-61.
[http://dx.doi.org/10.1146/annurev-virology-110615-042301] [PMID: 27578435]
[7]
Moore MJ, Dorfman T, Li W, et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol 2004; 78(19): 10628-35.
[http://dx.doi.org/10.1128/JVI.78.19.10628-10635.2004] [PMID: 15367630]
[8]
Premkumar L, Segovia-Chumbez B, Jadi R, et al. The RBD of the spike protein Of SARS-Group coronaviruses is a highly specific target of SARS-CoV-2 antibodies but not other pathogenic human and animal coronavirus antibodies. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.05.06.20093377]
[9]
Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020; 586(7830): 572-7.
[http://dx.doi.org/10.1038/s41586-020-2599-8] [PMID: 32726802]
[10]
Wu F, Zhao S, Yu B, et al. A new coronavirus associated] with human respiratory disease in China. Nature 2020; 579(7798): 265-9.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[11]
Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 2021; 384(23): 2212-8.
[http://dx.doi.org/10.1056/NEJMoa2105000] [PMID: 33882219]
[12]
Tracking SARS-CoV-2 variants. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants [Accessed on 08 February 2022].
[13]
Grubaugh ND, Petrone ME, Holmes EC. We shouldn’t worry when a virus mutates during disease outbreaks. Nat Microbiol 2020; 5(4): 529-30.
[http://dx.doi.org/10.1038/s41564-020-0690-4] [PMID: 32071422]
[14]
Liu S, Shen J, Fang S, et al. Genetic spectrum and distinct evolution patterns of SARS-CoV-2. Front Microbiol 2020; 11: 593548.
[http://dx.doi.org/10.3389/fmicb.2020.593548] [PMID: 33101264]
[15]
Tushir S, Kamanna S, Nath SS, et al. Proteo-Genomic analysis of SARS-CoV-2: A clinical landscape of single-nucleotide polymor-phisms, COVID-19 proteome, and host responses. J Proteome Res 2021; 20(3): 1591-601.
[http://dx.doi.org/10.1021/acs.jproteome.0c00808] [PMID: 33555895]
[16]
Rahimi A, Mirzazadeh A, Tavakolpour S. Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics 2021; 113(1 Pt 2): 1221-32.
[http://dx.doi.org/10.1016/j.ygeno.2020.09.059] [PMID: 33007398]
[17]
Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020; 27(3): 325-8.
[http://dx.doi.org/10.1016/j.chom.2020.02.001] [PMID: 32035028]
[18]
Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 2021; 592(7853): 277-82.
[http://dx.doi.org/10.1038/s41586-021-03291-y] [PMID: 33545711]
[19]
González-Candelas F, Shaw M-A, Phan T, et al. One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. Infect Genet Evol 2021; 92: 104869.
[http://dx.doi.org/10.1016/j.meegid.2021.104869] [PMID: 33915216]
[20]
Ahmadpour D, Ahmadpoor P, Rostaing L. Impact of circulating SARS-CoV-2 Mutant G614 on the COVID-19 pandemic. Iran J Kidney Dis 2020; 14(5): 331-4.
[PMID: 32943587]
[21]
Korber B, Fischer WM, Gnanakaran S, et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.04.29.069054]
[22]
Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell 2020; 182(4): 812-827.e19.
[http://dx.doi.org/10.1016/j.cell.2020.06.043] [PMID: 32697968]
[23]
Isabel S, Graña-Miraglia L, Gutierrez JM, et al. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci Rep 2020; 10(1): 14031.
[http://dx.doi.org/10.1038/s41598-020-70827-z] [PMID: 32820179]
[24]
Zhou B, Thao TTN, Hoffmann D, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 2021; 592(7852): 122-7.
[http://dx.doi.org/10.1038/s41586-021-03361-1] [PMID: 33636719]
[25]
Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol 2020; 11: 1800.
[http://dx.doi.org/10.3389/fmicb.2020.01800] [PMID: 32793182]
[26]
Bakhshandeh B, Jahanafrooz Z, Abbasi A, et al. Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. Microb Pathog 2021; 154: 104831.
[http://dx.doi.org/10.1016/j.micpath.2021.104831] [PMID: 33727169]
[27]
Centers for Disease Control and Prevention, 2021. SARS-CoV-2 Variant Classifications and Definitions. Available from: 2021.https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html [Accessed on 08 February 2022].
[28]
Rambaut A, Holmes EC, O’Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 2020; 5(11): 1403-7.
[http://dx.doi.org/10.1038/s41564-020-0770-5] [PMID: 32669681]
[29]
Alm E, Broberg EK, Connor T, et al. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region. Euro Surveill 2020; 25(32): 2001410.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.32.2001410] [PMID: 32794443]
[30]
Han AX, Parker E, Scholer F, Maurer-Stroh S, Russell CA. Phylogenetic clustering by linear integer programming (PhyCLIP). Mol Biol Evol 2019; 36(7): 1580-95.
[http://dx.doi.org/10.1093/molbev/msz053] [PMID: 30854550]
[31]
Hodcroft EB, Hadfield J, Neher RA, et al. Year-letter Genetic Clade Naming for SARS-CoV-2 Available from: https://nextstrain.org/blog/2020-06-02-SARSCoV2-clade-naming [Accessed on 08 February 2022].
[32]
Bedford T, Hodcroft EB, Neher RA. Updated Nextstain SARS-CoV-2 clade naming strategy 2021. Available from: https://virological.org/t/updated-nextstain-sars-cov-2-clade-naming-strategy/581 [Accessed on 08 February 2022].
[33]
www.cdc.gov. SARS-CoV-2 Variant Classifications and Definitions. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html [Accessed on 08 February 2022].
[34]
www.ecdc.europa.eu/enSARS-CoV-2 variants of concern as of 03 February 2022 2022. Available from: https://www.ecdc. europa.eu/en/covid-19/variants-concern [Accessed on 08 February 2022].
[35]
Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ 2020; 371: m4471.
[http://dx.doi.org/10.1136/bmj.m4471]
[36]
Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 2021; 27(5): 917-24.
[http://dx.doi.org/10.1038/s41591-021-01318-5] [PMID: 33772244]
[37]
Cherian S, Potdar V, Jadhav S, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and 681R. BioRxiv 2021.
[http://dx.doi.org/10.1101/2021.04.22.440932]
[38]
Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 2021; 184(9): 2384-2393.e12.
[http://dx.doi.org/10.1016/j.cell.2021.03.036] [PMID: 33794143]
[39]
Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021; 593(7857): 130-5.
[http://dx.doi.org/10.1038/s41586-021-03398-2] [PMID: 33684923]
[40]
He X, Hong W, Pan X, et al. Severe acute respiratory syndrome coronavirus 2 Omicron variant: Characteristics and prevention. MedComm 2021; 2: 838-45.
[http://dx.doi.org/10.1002/mco2.110] [PMID: 34957469]
[41]
Chen J, Wang R, Gilby NB, Wei GW. Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 2022; 62(2): 412-22.
[http://dx.doi.org/10.1021/acs.jcim.1c01451] [PMID: 34989238]
[42]
Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect 2022; 11(1): 337-43.
[http://dx.doi.org/10.1080/22221751.2021.2022440] [PMID: 34935594]
[43]
Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 And novel therapeutics against coronavirus (COVID-19). In: StatPearls Publishing: Treasure Island (FL) 2022.
[44]
Fall A, Eldesouki RE, Sachithanandham J, et al. A quick displacement of the SARS-CoV-2 variant delta with omicron: unprecedented spike in COVID-19 cases associated with fewer admissions and comparable upper respiratory viral loads. medRxiv 2022; 2022.01.26.22269927.
[http://dx.doi.org/10.1101/2022.01.26.22269927]
[45]
Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases 2022; 10(1): 1-11.
[http://dx.doi.org/10.12998/wjcc.v10.i1.1] [PMID: 35071500]
[46]
Fenner F, Henderson DA, Arita I, et al. Early efforts at control: Variolation, vaccination, and isolation and quarantine. History of Inter-national Public Health 1988; 6: 245-76.
[47]
Plotkin SL, Plotkin S. A short history of vaccination. Vaccines 2004; 5: 1-15.
[48]
Liu Y, Wang K, Massoud TF, Paulmurugan R. SARS-CoV-2 vaccine development: an overview and perspectives. ACS Pharmacol Transl Sci 2020; 3(5): 844-58.
[http://dx.doi.org/10.1021/acsptsci.0c00109] [PMID: 33062951]
[49]
Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. SARS-CoV-2 vaccines: Lights and shadows. Eur J Intern Med 2021; 88: 1-8.
[http://dx.doi.org/10.1016/j.ejim.2021.04.019] [PMID: 33966930]
[50]
Sathian B, Asim M, Banerjee I, et al. Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials. Nepal J Epidemiol 2021; 11(1): 959-82.
[http://dx.doi.org/10.3126/nje.v11i1.36163] [PMID: 33868742]
[51]
Kwok HF. Review of COVID-19 vaccine clinical trials - A puzzle with missing pieces. Int J Biol Sci 2021; 17(6): 1461-8.
[http://dx.doi.org/10.7150/ijbs.59170] [PMID: 33907509]
[52]
He Q, Mao Q, Zhang J, et al. COVID-19 Vaccines: current understanding on immunogenicity, safety, and further considerations. Front Immunol 2021; 12: 669339.
[http://dx.doi.org/10.3389/fimmu.2021.669339] [PMID: 33912196]
[53]
Holder J. Tracking coronavirus vaccinations around the world 2022. Available from: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html [Accessed on 08 February 2022].
[54]
Padron-Regalado E. Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect Dis Ther 2020; 9(2): 1-20.
[http://dx.doi.org/10.1007/s40121-020-00300-x] [PMID: 32328406]
[55]
Khoshnood S, Arshadi M, Akrami S, et al. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. J Clin Lab Anal 2022; 36(5): e24418.
[http://dx.doi.org/10.1002/jcla.24418] [PMID: 35421266]
[56]
Lundstrom K. Viral vectors for COVID-19 vaccine development. Viruses 2021; 13(2): 317.
[http://dx.doi.org/10.3390/v13020317]
[57]
Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel) 2014; 2(3): 624-41.
[http://dx.doi.org/10.3390/vaccines2030624] [PMID: 26344749]
[58]
Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infez Med 2021; 29(3): 328-38.
[http://dx.doi.org/10.53854/liim-2903-3] [PMID: 35146337]
[59]
Qin F, Xia F, Chen H, et al. A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: From basic principles to current applications. Front Cell Dev Biol 2021; 9: 633776.
[http://dx.doi.org/10.3389/fcell.2021.633776] [PMID: 34113610]
[60]
Belete TM. A review on promising vaccine development progress for COVID-19 disease. Vacunas 2020; 21(2): 121-8.
[http://dx.doi.org/10.1016/j.vacune.2020.10.009]
[61]
Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 2020; 11: 298.
[http://dx.doi.org/10.3389/fmicb.2020.00298] [PMID: 32265848]
[62]
Vaccine types 2019. Available from: https://www.niaid.nih.gov/research/vaccine-types [Accessed on 08 February 2022].
[63]
Roldão A, Mellado MCM, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines 2010; 9(10): 1149-76.
[http://dx.doi.org/10.1586/erv.10.115] [PMID: 20923267]
[64]
Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 2021; 19(1): 59.
[http://dx.doi.org/10.1186/s12951-021-00806-7] [PMID: 33632278]
[65]
COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-COVID-19-candidate-vaccines2020. [Accessed on 08 February 2022].
[66]
Coronavirus (COVID-19) Vaccinations. Available from: https://ourworldindata.org/covid-vaccinations2020. [Accessed on 21 April 2022].
[67]
Ling Y, Zhong J, Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis. J Med Virol 2021; 93(12): 6486-95.
[http://dx.doi.org/10.1002/jmv.27203] [PMID: 34264528]
[68]
Pfizer and Biontech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. 2021. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious [Accessed on 08 February 2022].
[69]
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[70]
Deplanque D, Launay O. Efficacy of COVID-19 vaccines: From clinical trials to real life. Therapie 2021; 76(4): 277-83.
[http://dx.doi.org/10.1016/j.therap.2021.05.004] [PMID: 34049688]
[71]
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99-111.
[http://dx.doi.org/10.1016/S0140-6736(20)32661-1] [PMID: 33306989]
[72]
Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 2021; 397(10269): 72-4.
[http://dx.doi.org/10.1016/S0140-6736(20)32623-4] [PMID: 33306990]
[73]
Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 Variant. N Engl J Med 2021; 384(20): 1885-98.
[http://dx.doi.org/10.1056/NEJMoa2102214] [PMID: 33725432]
[74]
Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet 2021; 397(10282): 1351-62.
[http://dx.doi.org/10.1016/S0140-6736(21)00628-0] [PMID: 33798499]
[75]
Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021; 384(20): 1899-909.
[http://dx.doi.org/10.1056/NEJMoa2103055] [PMID: 33951374]
[76]
Xing K, Tu XY, Liu M, et al. Efficacy and safety of COVID-19 vaccines: A systematic review. Zhongguo Dang Dai Er Ke Za Zhi 2021; 23(3): 221-8.
[http://dx.doi.org/10.7499/j.issn.1008-8830.2101133] [PMID: 33691913]
[77]
Sallam M, Al-Sanafi M, Sallam M. A global map of COVID-19 vaccine acceptance rates per country: An updated concise narrative Re-view. J Multidiscip Healthc 2022; 15: 21-45.
[http://dx.doi.org/10.2147/JMDH.S347669] [PMID: 35046661]
[78]
Dubé E, MacDonald NE. COVID-19 vaccine hesitancy. Nat Rev Nephrol 2022; 1-2.
[http://dx.doi.org/10.1038/s41581-022-00571-2] [PMID: 35414006]
[79]
Yousaf M, Hassan Raza S, Mahmood N, Core R, Zaman U, Malik A. Immunity debt or vaccination crisis? A multi-method evidence on vaccine acceptance and media framing for emerging COVID-19 variants. Vaccine 2022; 40(12): 1855-63.
[http://dx.doi.org/10.1016/j.vaccine.2022.01.055] [PMID: 35153094]
[80]
Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. Lancet Infect Dis 2022; (22): 00146-3.
[http://dx.doi.org/10.1016/S1473-3099(22)00146-3]
[81]
Rates of COVID-19 Cases and Deaths by Vaccination Status. 2022. Available from: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status [Accessed on 21 April 2022.
[82]
Choi WS, Cheong HJ. COVID-19 vaccination for people with comorbidities. Infect Chemother 2021; 53(1): 155-8.
[http://dx.doi.org/10.3947/ic.2021.0302] [PMID: 34409789]
[83]
Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 2021; 50(2): 279-83.
[http://dx.doi.org/10.1093/ageing/afaa274] [PMID: 33320183]
[84]
Ho JS, Sia CH, Ngiam JN, et al. A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J 2021.
[http://dx.doi.org/10.11622/smedj.2021210] [PMID: 34808708]
[85]
Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr 2021; 15(2): 505-8.
[http://dx.doi.org/10.1016/j.dsx.2021.02.026] [PMID: 33662837]
[86]
Bouwmans P, Messchendorp AL, Sanders JS, et al. Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study. BMC Nephrol 2022; 23(1): 55.
[http://dx.doi.org/10.1186/s12882-022-02680-3] [PMID: 35123437]
[87]
Rates of laboratory-confirmed COVID-19 hospitalizations by vaccination status 2022. Available from: https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination [Accessed on 22 April 2022].
[88]
Alsaffar WA, Alwesaibi AA, Alhaddad MJ, et al. The effectiveness of COVID-19 vaccines in improving the outcomes of hospitalized COVID-19 patients. Cureus 2022; 14(1): e21485.
[http://dx.doi.org/10.7759/cureus.21485] [PMID: 35103227]
[89]
Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis. Int J Infect Dis 2022; 114: 252-60.
[http://dx.doi.org/10.1016/j.ijid.2021.11.009] [PMID: 34800687]
[90]
Monitoring COVID-19 Vaccine Effectiveness. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/how-they-work.html [Accessed on 08 February 2022].
[91]
COVID-19 vaccine efficacy summary. 2022. Available from: https://www.healthdata.org/covid/covid-19-vaccine-efficacy-summary [Accessed on 08 February 2022].
[92]
Singh PK, Kulsum U, Rufai SB, Mudliar SR, Singh S. Mutations in SARS-CoV-2 leading to antigenic variations in spike protein: A chal-lenge in vaccine development. J Lab Physicians 2020; 12(2): 154-60.
[http://dx.doi.org/10.1055/s-0040-1715790] [PMID: 32884216]
[93]
Bar-Zeev N, Kochhar S. Expecting the unexpected with COVID-19 vaccines. Lancet Infect Dis 2021; 21(2): 150-1.
[http://dx.doi.org/10.1016/S1473-3099(20)30870-7] [PMID: 33217363]
[94]
Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(10): 667-8.
[http://dx.doi.org/10.1038/d41573-020-00151-8] [PMID: 32887942]
[95]
Yi C, Sun X, Ye J, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 2020; 17(6): 621-30.
[http://dx.doi.org/10.1038/s41423-020-0458-z] [PMID: 32415260]
[96]
Sesterhenn F, Yang C, Bonet J, et al. De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science 2020; 368(6492): eaay5051.
[http://dx.doi.org/10.1126/science.aay5051] [PMID: 32409444]
[97]
Tian L, Wang HN, Lu D, Zhang YF, Wang T, Kang RM. The immunoreactivity of a chimeric multi-epitope DNA vaccine against IBV in chickens. Biochem Biophys Res Commun 2008; 377(1): 221-5.
[http://dx.doi.org/10.1016/j.bbrc.2008.09.125] [PMID: 18840402]
[98]
Saylor K, Gillam F, Lohneis T, Zhang C. Designs of antigen structure and composition for improved protein-based vaccine efficacy. Front Immunol 2020; 11: 283.
[http://dx.doi.org/10.3389/fimmu.2020.00283] [PMID: 32153587]
[99]
Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin Microbiol Infect 2022; 28(2): 202-21.
[http://dx.doi.org/10.1016/j.cmi.2021.10.005] [PMID: 34715347]
[100]
COVID-19 Vaccine Boosters. 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html [Accessed on 22 April 2022].
[101]
Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022; 386(11): 1046-57.
[http://dx.doi.org/10.1056/NEJMoa2116414] [PMID: 35081293]
[102]
Yang T, Wang HN, Wang X, et al. Multivalent DNA vaccine enhanced protection efficacy against infectious bronchitis virus in chickens. J Vet Med Sci 2009; 71(12): 1585-90.
[http://dx.doi.org/10.1292/jvms.001585] [PMID: 20046025]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy